US Senator Richard Blumenthal (D-CT) (Photo by Michael Brochstein/Sipa USA)(Sipa via AP Images)

May 5, 2022 02:08 PM EDTUpdated May 6, 06:15 PM

PBMs in the Senate hot seat as bipartisan transparency measures may take root

Zachary Brennan

Senior Editor

Pharmacy benefit managers ⁠— the much-maligned middlemen of the pharmaceutical supply chain ⁠— took the brunt of questioning from senators on both sides of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PBMs in the Senate hot seat as bipartisan transparency measures may take root

Zachary Brennan

Senior Editor

Sign up to read this article for free.

NIH’s funding cut plan poses challenges for researchers despite court halt

AbbVie pens another T cell engager deal, this time with Xilio

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

Kaiser Permanente calls on FDA and Congress to firm up accelerated approval requirements

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

PBMs in the Sen­ate hot seat as bi­par­ti­san trans­paren­cy mea­sures may take root

Zachary Brennan

Senior Editor

Sign up to read this article for free.

NIH’s fund­ing cut plan pos­es chal­lenges for re­searchers de­spite court halt

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis

Bio­gen down­plays ca­pac­i­ty for M&A; Roche’s SMA drug is ap­proved as a tablet

Kaiser Per­ma­nente calls on FDA and Con­gress to firm up ac­cel­er­at­ed ap­proval re­quire­ments

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

PBMs in the Senate hot seat as bipartisan transparency measures may take root

NIH’s funding cut plan poses challenges for researchers despite court halt

AbbVie pens another T cell engager deal, this time with Xilio

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

Kaiser Permanente calls on FDA and Congress to firm up accelerated approval requirements

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers